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external experts. Multivariate analysis using Cox’s hazard 
model identified the risk factors.
Results ILD incidence (1.3 %) and mortality rates 
(51.3 %) were similar to those of patients receiving another 
anti-epidermal growth factor receptor (EGFR) monoclo-
nal antibody in Japan. No specific onset timing was deter-
mined. Although panitumumab-specific ILD findings were 
not observed in computed tomography images or clinical 
practice, panitumumab can induce ILD with diffuse alveo-
lar damage, as do the other anti-EGFR targeting drugs. A 
history/complication of ILD, male sex, poor general con-
dition, and 65 years or older were identified as ILD risk 
factors, and no history of previous drug treatment was an 
apparent risk factor.
Conclusion Panitumumab-induced ILD can occur at any 
time after initiation, and close and regular monitoring is 
needed.
Keywords Colorectal cancer · Interstitial lung disease · 
Panitumumab · Postmarketing surveillance · Risk factors
Introduction
Panitumumab is a high-affinity, fully human monoclo-
nal antibody targeting epidermal growth factor receptor 
(EGFR) [1]. Panitumumab was first approved for the treat-
ment of patients with EGFR-expressing metastatic colorec-
tal cancer as monotherapy in the USA in 2006, based on the 
results of a multinational, open-label, randomized phase III 
study showing an improvement in the median progression-
free survival [2].
In Japan, panitumumab was approved in 2010 for the 
treatment of wild-type KRAS unresectable, advanced or 
recurrent colorectal cancer as monotherapy, and for use in 
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combination therapy in all-line treatment settings based on 
the global clinical trials and a Japanese phase II trial [3–9]. 
As a condition for its approval, the Japanese Ministry of 
Health, Labour and Welfare requested the implementation 
of a postmarketing all-case surveillance study to confirm 
the safety and efficacy of panitumumab in the clinical set-
ting because the number of Japanese patients enrolled in the 
global and Japanese clinical trials was limited. Hence, the 
postmarketing all-case surveillance study was conducted in 
Japan. Following is a summary of the survey results from 
3085 enrolled patients [10]: (a) the favorable toxicity pro-
file and clinical benefit of panitumumab treatment in daily 
clinical practice were confirmed, and were similar to those 
reported in the previous clinical trials; and (b) the most 
common adverse drug reaction observed was skin disorders 
(78.4 %), including dermatitis acneiform, paronychia, dry 
skin, and pruritus, followed by electrolyte abnormalities 
(19.3 %), infusion reaction (1.5 %), interstitial lung disease 
(ILD) (1.3 %), and cardiac disorders (0.2 %).
Drug-induced ILD is noted as one of the most seri-
ous adverse reactions associated with molecular target-
ing agents including an anti-EGFR monoclonal antibody 
(cetuximab) and EGFR-tyrosine kinase inhibitors (TKIs) 
(gefitinib and erlotinib), as it can be fatal [11–20]. Multi-
ple studies have reported that the incidence of drug-induced 
ILD was higher in Japan than in other countries, and this 
trend was more prominently observed in the postmarket-
ing surveillance studies of the EGFR-TKIs [13–15, 21] and 
anti-EGFR antibody [20].
There were no adverse drug reaction reports of ILD in 
panitumumab monotherapy (1052 patients) prior to its 
approval in Japan; however, such reports were received 
in combined therapy with FOLFOX4 (fluorouracil, leuco-
vorin, and oxaliplatin) [0.6 % (2/322 patients)] and with 
FOLFIRI (fluorouracil, leucovorin, and irinotecan) [0.7 % 
(2/302 patients)] [10]. In addition, during the course of 
clinical trials, a patient with non-small-cell lung cancer 
who had a history of pulmonary fibrosis developed ILD 
and died. Thereafter, patients with a history of or current 
ILD were excluded from clinical trials, and the experience 
of administration to patients with a history of ILD was 
limited. It is therefore important to evaluate the clinical 
features and risk factors of panitumumab-induced ILD to 
prevent the fatal outcome of ILD as well as to ensure an 
appropriate use of the drug.
Materials and methods
Patients and surveillance design
This postmarketing surveillance study was planned to 
include all patients treated with panitumumab (Vectibix) 
from the start date (June 15, 2010) of its launch in Japan 
(ClinicalTrials.gov: NCT02089737; Japan Pharmaceutical 
Information Center–Clinical Trials Information: 132374) 
[10].
To promote appropriate use and evaluate safety infor-
mation, a Vectibix Appropriate Use Committee, a Vectibix 
Safety Evaluation Committee, and a Vectibix ILD review 
subcommittee were organized. The Vectibix ILD review 
subcommittee was established to evaluate the relationship 
between panitumumab and ILD, or the tendency of ILD 
occurrence, from the viewpoint of a third party on the basis 
of information on the treatment of patients in whom ILD 
developed or who had symptoms or disease states related 
to ILD after they received panitumumab. The registration 
period of this postmarketing surveillance study was from 
June 2010 to November 2010.
All patients were registered by fax before their first 
administration of panitumumab after panitumumab was 
marketed. Regarding ILD risk, a letter recommending to 
avoid administration was sent from the Vectibix Appropri-
ate Use Committee if the patient had a history of ILD or 
pulmonary fibrosis and previous or concurrent ILD with 
the FOLFIRI regimen. A letter recommending to recon-
sider the administration was sent if the patient had a history 
of ILD.
Data on patients’ demographics, clinical course, and 
safety information were collected using a case report form 
at 10 months after the start of the panitumumab therapy or 
at the time when the therapy was discontinued for any rea-
son within less than 10 months. Reported terms were clas-
sified according to the Preferred Terms in the Medical Dic-
tionary for Regulatory Activities (MedDRA), version 15.0.
Evaluation of ILD
The Vectibix ILD review subcommittee (hereafter referred 
to as the committee) was established before this survey was 
performed. The committee consisted of the following 5 
external experts to assess ILD case reports appropriately: 
2 experts in radiology, 2 in pulmonology, and 1 in medi-
cal oncology. ILD and potential ILD case reports were then 
evaluated according to the flowchart shown in Fig. 1. Radi-
ologic images were analyzed in the current study according 
to the diagnostic criteria determined by the American Tho-
racic Society/European Thoracic Society. The committee 
gave not only evaluations of each individual case, but also 
advice on further investigations and safety measures. The 
committee was convened 10 times from November 2010 to 
December 2012.
If a reported term was contained within the Standard 
MedDRA Query (SMQ) “ILD” (narrow and broad), the 
event was required to be reviewed by the committee. If 
potential ILD events including pulmonary toxicities such as 
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pneumonia, dyspnea, acute respiratory failure, and pulmo-
nary edema that were not included in the SMQ “ILD” were 
indicated, these patients were assessed by the committee 
after a medical review.
If ILD or potential ILD was reported, detailed clini-
cal information, including laboratory data, and treatment 
and medical histories were additionally collected and the 
reporting physicians were requested to submit the radio-
graphic and computed tomography (CT) images.
Statistical analysis
Exploratory multivariate analysis was performed to inves-
tigate risk factors for ILD. Two ILD events considered by 
the committee not to be related to panitumumab were also 
included in the analyses to avoid a bias. Any patient who 
developed ILD more than 10 months after the first admin-
istration was excluded. The potential variables were first 
selected based on the stratified frequency of ILD. The med-
ical interests of ILD and dependency variables were taken 
into account, and the major variables were selected and 
multivariate analysis in a stepwise manner was performed 
using Cox’s proportional hazards model (Table 1). The fol-
lowing variables were contained as explanatory variables: 
sex, age, Eastern Cooperative Oncology Group Perfor-
mance Status (ECOG PS), previous or concurrent ILD, pre-
vious drug treatment for colorectal cancer, a concomitant 
chemotherapy with FOLFOX, and smoking status. The 




Forty-eight possible ILD case reports were evaluated and 
39 events were determined to be panitumumab-induced 
ILD (Fig. 1). Patient demographics are shown in Table 2. 
Five of the 9 excluded patients were reported by primary 
physicians to have either a history of or concurrent ILD. In 
addition, 4 patients were excluded as they were considered 
by the committee, based on the evaluation of images, to 
have either a history or a complication of ILD, although the 
primary physicians reported that they had neither a history 
nor a complication of ILD.
The total ILD frequency was 1.3 % (39/3085) [mono-
therapy group: 1.3 % (16/1254); combination therapy 
Fig. 1  Diagnosis of ILD. 
ILD cases were evaluated and 
determined according to the 
flowchart. The ILD review sub-
committee assessed each ILD 
case report based on the clinical 
and radiographic findings. ILD 
interstitial lung disease
As needed
Safety analysis set in all-case surveillance N = 3085
ILD patients (reported by physicians) Potential ILD patients
Review by ILD subcommittee n = 48
ILD (reported by physicians) n = 45 (unrelated to panitumumab n = 3)
Pneumonia n = 2
Dyspnea n = 1
Assessed as unrelated to panitumumab by ILD subcommittee n = 9
Reason for ruling these cases out
Denied the possibility of drug induced ILD n = 7
Results of evaluation n Reported term
Pneumonia 1 Pneumonia
Pneumocystis jiroveci pneumonia 1 ILD
Infectious pneumonia 3 ILD 2Pneumonia 1
Pulmonary edema 1 ILD
Infection/cardiac failure/
pulmonary edema 1 ILD
Suspected other drugs (CPT-11, S-1/bevacizumab) n = 2
ILD patients whose causal relationship between panitumumab cannot be ruled out
(assessment by the ILD subcommittee) n = 39 (1.3%, 39/3085)
Medical review
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group: 1.3 % (23/1831); combination therapy with FOL-
FOX group: 2.3 % (13/573); combination therapy with 
FOLFIRI group: 1.2 % (13/1045); others: 0.5 % (1/191)]. 
The committee concluded that the mortality due to ILD 
was 51.3 % (20/39). Although the reporting physicians 
regarded that 3 patients among those who had ILD onset 
died due to their primary disease, it was considered that a 
causal relationship between the ILD and the death could 
not be ruled out by the committee. Therefore, they were 
included as fatal ILD.
Imaging pattern
A diffuse alveolar damage (DAD) pattern was identified in 
18 patients, including 5 patients who developed ILD with a 
non-DAD pattern at an earlier time point of panitumumab 
administration and progressed to ILD with DAD. Hyper-
sensitivity (HP) and organizing pneumonia (OP) were also 
found in 9 and 8 patients, respectively. Two ILD patients 
whose imaging data were not provided were assessed based 
on the clinical course and laboratory data. The imaging pat-
terns were categorized as “unknown.”
The mortality rate of patients with DAD was 83.3 % 
(15/18), while that of patients with non-DAD patterns, i.e., 
HP and OP, was 11.8 % (2/17) (Table 3).
Timing of ILD onset
Figure 2 and Table 3 show the number of ILD patients and 
the length of time to the onset of ILD. No significant cor-
relations were found between the timing of ILD onset and 
the imaging patterns (time to onset from start of adminis-
tration: 2–313 days; 1–19 courses). In 11 patients, ILD 
occurred 6 months or longer after the first administration of 
panitumumab.
Risk factors
Of the 3085 patients, 774 (25.1 %), including several who 
developed ILD, were excluded from the multivariate analy-
sis because of unknown background information (informa-
tion about a smoking history in 773 patients and a prior 
treatment history in 1 patient was not available). Therefore, 
only 2311 patients were used for the multivariate analysis. 
Of these patients, 34 were assessed to have ILD.
Among the 34 patients, the risk of ILD occurrence was 
significantly higher in those with a history/complication 
of ILD, no history of previous drug treatment, and male 
sex (Table 4; Fig. 3). The adjusted hazard ratio (HR) was 
greater than 2.0 in the groups of 65 years or older and 
ECOG PS 2–4.
Discussion
In order to manage and prevent fatal outcomes due to ILD, 
the current study focused on the clinical features and risk 
factors of panitumumab-induced ILD. Several postmar-
keting surveillance studies have suggested that the fre-
quency of drug-induced ILD was higher in Japan than in 
other countries [13, 15, 16, 20, 21]. This difference might 
be due to many reasons: e.g., genetic susceptibility based 
on the different genetic background, underlying comor-
bidity, previous environmental exposures, clinical prac-
tices, frequency of diagnosis device, detection bias, and 
preference of reporting terms [15]. In the clinical trials of 
Table 1  Method of multivariate analysis
ILD interstitial lung disease, ECOG PS Eastern Cooperative Oncology Group Performance Status
a Gender, age, ECOG PS and smoking status were set as variables when a model was selected
Statistical method Multivariate analysis using Cox’s proportional hazards model, stepwise 
processa, level of significance 5 %
Analysis population 2311 patients who had the full set of explanatory variables among 3085 
patients who participated in the safety analysis
Response variable
 ILD (diagnosis by the ILD review subcommittee, adverse events) Yes/no
Explanatory variable
 Sex Male/female
 Age <65 years/≥65 years
 ECOG PS PS: 0, 1/PS: 2–4
 Previous or concurrent ILD No/yes
 Previous drug treatment for colorectal cancer No/yes
 Concomitant chemotherapy FOLFOX No/yes
 Smoking status No/yes (smoking and smoked in the past)
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panitumumab monotherapy in metastatic colorectal cancer 
involving 1052 patients, there were no reports of adverse 
drug reactions in patients considered to have panitumumab-
induced ILD, while in the clinical trials of the combination 
therapy with FOLFIRI [8] and with FOLFOX4 [7], adverse 
drug reactions considered to be panitumumab-induced ILD 
were reported at the rate of 0.7 % (2/302 patients; fatal, 
0/2) and 0.6 % (2/322 patients; fatal due to ILD, 2/2), 
respectively. The incidence rate of ILD in this postmarket-
ing all-case surveillance study in Japan was 1.3 % (39/3085 
patients; fatal due to ILD, 20/39), which appeared slightly 
higher than that observed in premarketing clinical trials. Of 
the 20 patients who died due to ILD, 15 patients exhibited 
a DAD pattern and most of the patients were treated with 
steroid administration, but in 1 patient the treatment was 
considered to have been initiated late. Among the 20 deaths 
due to ILD, 3 out of 5 patients (including 3 non-evaluable 
patients) with a non-DAD pattern were treated with ster-
oid administration, while the information regarding steroid 
treatment in the remaining 2 patients was missing. The ILD 
incidence and mortality rates were similar to those of the 
other anti-EGFR antibody [17, 20]. Data on the patients 
who died and those who did not were reviewed, but no 
particular differences in background factors or time to ILD 
onset, excluding a higher mortality rate in patients with a 
DAD pattern, were found between the 2 groups.
It is beneficial for clinicians to understand the clinical 
features of drug-induced ILD in daily medical practice. For 
instance, capillary leak syndrome by bortezomib adminis-
tration [22] and high frequency of grade 1–2 ILD by mam-
malian target of rapamycin (mTOR) inhibitor [23] are 
examples of specific ILD features related to molecularly 
targeted drugs [16]. Panitumumab as well as cetuximab and 
EGFR-TKIs such as gefitinib and erlotinib can induce ILD 
with a DAD pattern, which can sometimes lead to a fatal 
outcome [24–26]. However, in this study, no findings spe-
cific to panitumumab were identified based on CT images 
or clinical practice.
Table 2  Patient demographics




n % n %
Gender
 Male 1965 63.7 32 1.6
 Female 1120 36.3 7 0.6
Age
 <65 years 1524 49.4 13 0.9
 65–74 years 1058 34.3 16 1.5
 ≥75 years 503 16.3 10 2.0
 Median (range) 65.0 (18–90) – 69.0 (40–90)
KRAS status
 Wild 3003 97.3 37 1.2
 Mutant 3 0.1 1 33.3
 Not determinable 79 2.6 1 1.3
ECOG PS
 0 1877 60.8 23 1.2
 1 942 30.5 10 1.1
 2 241 7.8 5 2.1
 3 22 0.7 1 4.5
 4 3 0.1 0 0.0
Treatment lines
 First line 310 10.1 11 3.5
 Second line 543 17.6 8 1.5
 Third line or later 2232 72.4 20 0.9
Past treatment regimens
 No 173 5.6 8 4.6
 Yes (duplicate counting) 2911 94.4 31 1.1
  FOLFOX 2439 79.1 25 1.0
  FOLFIRI 1907 61.8 20 1.0
  Bevacizumab 2113 68.5 23 1.1
  Cetuximab 917 29.7 9 1.0
  Others 2067 67.0 23 1.1
 Unknown 1 0.0 0 0
Treatment regimen
 Monotherapy 1254 40.7 16 1.3
 Chemotherapy (duplicate 
counting)
1831 59.4 23 1.3
  FOLFOX 573 18.6 13 2.3
  FOLFIRI 1045 33.9 13 1.2
  CPT-11 277 9.0 0 0.0
  Others 191 6.2 1 0.5
Smoking history
 No 1365 44.3 14 1.0
 Yes 947 30.7 19 2.0
  Current smoking 234 7.6 5 2.1
  Smoked in the past 713 23.1 14 2.0
 Unknown 773 25.1 6 0.8
ECOG PS Eastern Cooperative Oncology Group Performance Status, 
ILD interstitial lung disease
a Detected by the ILD review subcommittee
Table 2  continued




n % n %
Previous or concurrent ILD
 No 3051 98.9 34 1.1
 Yes (reported by  
physicians)
34 1.1 5 14.7
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It has been reported that an early onset of ILD occur-
rence was observed during EGFR-TKI administration [13]. 
Since no specific time-onset of ILD occurrence was found 
when panitumumab, as well as cetuximab, was adminis-
tered, close and regular pulmonary monitoring is important 
for panitumumab administration.
From the results of the multivariate analysis, a history/
complication of ILD, no history of previous drug treatment, 
and male sex were considered to be significant risk factors 
for panitumumab-induced ILDs. ECOG PS 2–4 and age 
of 65 years or older were also indicated as potential risk 
factors. These risk factors for ILD associated with panitu-
mumab use are almost the same as those reported for the 
EGFR-TKIs [13, 14, 18, 19] and the other anti-EGFR mon-
oclonal antibody [20]. No history of previous drug treat-
ment could be an apparent risk factor because of patient 
selection bias. The reasons are as follows: 666 patients 
previously treated with the other anti-EGFR monoclonal 
antibody, cetuximab, were included in the 2180 patients 
with previous treatment. These patients were considered 
to be less likely to experience ILD even when treated with 
panitumumab (the incidence of ILD was 0.66 % [6/914] in 
patients who received panitumumab among patients who 
had received the other anti-EGFR monoclonal antibody 
and had not experienced ILD). In addition to the patient 
selection bias, it was unlikely that the patients undergo-
ing first-line treatment had a higher risk of ILD than those 
undergoing second-line or later treatment, because, gener-
ally speaking, a patient undergoing second-line or later 
treatment had disease progression and their general condi-
tion was worse. Similarly, the incidence of ILD was sig-
nificantly higher in elderly patients and those who had prior 
ILD, according to the results of postmarketing all-case sur-
veillance of cetuximab in Japan [20]. In this study, cetux-
imab was used as second-line or later therapy after some 
chemotherapy [17]. The risk factors for ILD occurrence 
during therapy with an anti-EGFR monoclonal antibody 
need further investigation.
The following 3 factors are important for detecting ILD 
at an early stage: (1) examining whether patients have signs 
or symptoms such as dry cough, dyspnoea, and pyrexia 
which suggest the patients have ILD, and consulting with 
pulmonologists at an early stage if the signs or symptoms 
are found; (2) informing patients or their family of signs or 
symptoms of ILD in advance and counseling the patients 
to see a physician and report the signs or symptoms imme-
diately after onset; and (3) examining images of patients at 
the following times: (a) when physicians evaluate whether 
patients have lung metastasis before panitumumab is 
administered; (b) when the efficacy of panitumumab is 
evaluated; and (c) when signs or findings that show patients 
are suspected of having ILD are obtained.
The following are considered to be limitations in the cur-
rent analysis: (A) the all-case surveillance was not designed 
to identify ILD risk factors, and therefore only selected risk 
factors (listed in Table 4) were taken into consideration; (B) 
adverse events of both the monotherapy and combination 
chemotherapy were analyzed together, and thus impacts of 
the combination chemotherapy could not be excluded; and 
(C) since 773 patients without information on smoking, a 
Table 3  Number of ILD patients and length of time to the onset of ILD for each image pattern
Numbers of fatal cases are given in parentheses
ILD interstitial lung disease, DAD diffuse alveolar damage, HP hypersensitivity pneumonia, OP organizing pneumonia
Duration (months) Total ≤1 ≤2 ≤3 ≤4 ≤5 ≤6 ≤7 ≤8 ≤9 ≤10 >10
Number of patients 3085 2874 2570 2157 1774 1454 1210 1010 867 720 597 451
Number of ILD patients 39 (20) 8 (6) 4 (2) 11 (4) 1 (0) 4 (2) 5 (2) 0 (0) 3 (1) 2 (2) 0 (0) 1 (1)
Image pattern
 DAD 18 (15) 4 (4) 1 (1) 6 (4) 1 (0) 2 (2) 2 (2) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
 HP 9 (1) 1 (0) 1 (1) 3 (0) 0 (0) 1 (0) 1 (0) 0 (0) 2 (0) 0 (0) 0 (0) 0 (0)
 OP 8 (1) 1 (0) 2 (0) 2 (0) 0 (0) 1 (0) 1 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
 Unknown 4 (3) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)


















Fig. 2  Time to onset of ILD. The numbers of ILD cases assessed by 
the ILD review subcommittee were classified by the length of time to 
the onset of ILD. Each outcome consists of non-fatal (grey) and fatal 
(black) cases. Note that there were no specific trends of ILD occur-
rence observed during the study. ILD interstitial lung disease
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risk factor of ILD, were excluded from the analysis, the 
impact of smoking could not be fully considered. A ben-
efit–risk balance must be thoroughly considered before 
giving the drug to patients with interstitial pneumonia 
or lung fibrosis or those who have histories of them, and 
careful decisions must be made when deciding to initiate 
panitumumab.
In conclusion, the ILD incidence mortality rates and risk 
factors of panitumumab were similar to those of the other 
anti-EGFR monoclonal antibody [17, 20]. Panitumumab-
specific ILD findings were not observed in CT images or 
clinical practice. Panitumumab likely induces DAD just as 
the other anti-EGFR monoclonal antibody and EGFR-TKIs 
do, which may lead to death. A history/complication of 
ILD, male sex, poor general condition, and age of 65 years 
or older were indicated to be ILD risk factors in the mul-
tivariate analysis, and these are similarly observed in the 
reports with the EGFR-TKIs and anti-EGFR monoclonal 
antibody [13, 14, 20]. In addition, no history of previous 
drug treatment was considered to be an apparent risk factor. 
ILD can occur at any time after initiating panitumumab, 
and therefore close and regular monitoring is needed. 
Although several papers show that the frequency of EGFR-
TKI-induced ILD was higher in Japan than in Western 
countries [12, 18, 19], the reason was unclear. Some studies 
suggest that genetic differences make a contribution [27, 
28]. Anti-EGFR monoclonal antibodies might have similar 
mechanisms to EGFR-TKIs, and therefore ILD incidence 
is higher in Japan. Future studies are clearly warranted to 
investigate the benefit–risk balance in patients with the risk 
factors identified in this study.
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